Evaluation of the safety and efficacy of lascufloxacin for Legionella pneumonia

Evaluation of the safety and efficacy of lascufloxacin for Legionella pneumonia - Safety and efficacy of lascufloxacin for Legionella

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000049139

Enrollment

Registered

2022-10-06

Start date

2022-10-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Legionella pneumonia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hospitalized patients, aged 15 years or more, diagnosed with Legionella pneumonia. Community-onset pneumonia patients. Patients who consent to participation in the study (consent by proxy is permitted).

Exclusion criteria

Exclusion criteria: Patients treated with antibiotics other than lascufloxacin.

Design outcomes

Primary

Measure	Time frame
1. 30-day mortality 2. In-hospital mortality	—

Secondary

Measure	Time frame
1. Duration of admission 2. Pneumonia recurrence requiring antibiotic therapy 3. Time to defervescence from start of lascufloxacin (Defervescence was defined in days after the first 24 hours from less than 37.8 degree Celsius or less than 37.0 degree Celsius) 4. Intensive care unit admission, ventilatory support and vasopressor use due to exacerbation of pneumonia 5. Adverse drug effects	—

Countries

Japan

Contacts

Public ContactAkihiro Ito

Ohara Healthcare Foundation, Kurashiki Central Hospital Department of Respiratory Medicine

ai12306@kchnet.or.jp086-422-0210

Outcome results